12:00 AM
 | 
Jan 12, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CB-182: Phase I start

This quarter, Cubist will begin a Phase I trial to evaluate a single dose of intravenous...

Read the full 60 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >